Endo Pharmaceuticals
1400 Atwater Drive
Malvern
Pennsylvania
19355
United States
Tel: 484-216-0000
Website: http://www.endo.com/
305 articles with Endo Pharmaceuticals
-
Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor
7/1/2022
Endo International plc (NASDAQ: ENDP) announced today that a federal jury in Chicago, Illinois, has returned a verdict in favor of the Company's subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. (collectively Endo), in an antitrust trial.
-
Texas’ top law enforcement official is taking aim at two drug companies over what he alleges is the promotion of hormone blockers for children experiencing gender dysphoria.
-
The Oklahoma Supreme Court has overturned the landmark $465 million opioid verdict handed down against Johnson & Johnson in 2019.
-
Kaiser Sues Merck, Generic Drug Firm Over Millions in Losses Due to Alleged "Pay-for-Delay" Scheme
7/29/2021
Kaiser Permanente has reportedly filed a lawsuit against drug maker Merck for allegedly allowing a "pay-for-delay" scheme that cost the former millions of dollars. -
Tennessee Court Of Appeals Issues Orders Regarding State Court Default Judgment Against Endo
6/11/2021
Endo International plc today announced that the Tennessee Court of Appeals recently issued several orders with respect to a default judgment order on liability entered by the Circuit Court for Sullivan County, Tennessee in April 2021 against its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals.
-
BioSpecifics Announces Completion of Acquisition by Endo Pharmaceuticals
12/2/2020
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced the successful completion of its acquisition by Endo International plc (End
-
Endo Settles Opioid Investigation with State of Oklahoma for $8.75 million
1/10/2020
Endo International plc today announced that its subsidiaries Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc. have executed a Settlement Agreement with the State of Oklahoma.
-
Football Legend John Elway Reveals He has Dupuytren's Contracture and Wants Others to Get the "Facts on Hand"
8/22/2019
Elway joins campaign aimed at encouraging those who think they may have Dupuytren's contracture to seek a diagnosis from a hand specialist and ask about treatments, including nonsurgical options
-
Perrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray
8/21/2019
Annual market sales for the 12-months ending June 2019 were $90 million as measured by IQVIA™.
-
Teva Pharmaceuticals, Endo Pharmaceuticals and Taikoku Pharma entered into settlement agreements with the State of California for a total of almost $70 million. The settlements were over non-competitive, inter-company deals that prevented cheaper drugs from entering the market.
-
Nationally Recognized Urologist and Author, Aaron Spitz, MD, Teams Up with Endo Pharmaceuticals' Ask About the Curve Campaign to Encourage Men to Get "In Touch" With Their Anatomy This Men's Health Month
6/6/2019
Ask About the Curve raises awareness of Peyronie's disease, a men's health condition that may affect about 1 in 10 men and leads to a pronounced curvature in the penis and potential pain during arousal.
-
Perrigo Confirms Patent Challenge for Generic Version of Nascobal®
3/5/2019
This action formally initiates the litigation process under the Hatch-Waxman Act.
-
Baron & Budd Secures $13.25 Million to Settle Texas Whistleblower Lawsuit Against Endo Pharmaceuticals for Fraudulently Marketing Lidoderm for Unapproved Uses
8/1/2018
Today, the national law firm of Baron & Budd announced that Endo Pharmaceuticals. (“Endo”) has agreed to pay $13.25 million to settle a whistleblower lawsuit brought by the State of Texas under the Texas Medicaid Fraud Prevention Act (“TMFPA”).
-
Endo Announces Master Settlement Agreement Allowing for Resolution of Known Testosterone Replacement Therapy Product Liability Claims and Entry of Significant Case Management Order
6/11/2018
Endo International plc announced that its subsidiaries Endo Pharmaceuticals Inc. and Auxilium Pharmaceuticals, LLC have executed a definitive master settlement agreement allowing for the resolution of all known testosterone replacement therapy product liability claims against the Company.
-
Sitting before a Congressional panel Tuesday the heads of pharmaceutical distributing companies said their mea culpas over not doing more to limit the flow of prescription opioids to certain parts of the country.
-
Utah’s Salt Lake County is the latest governing body to enter the legal battle against opioid manufacturers, distributors and prescribers. Governments are seeking financial restitution for the funds they have spent on battling addiction to prescription opioid medications.
-
As legal battles over opioid drugs slowly move through the courts the U.S. Department of Justice is adding its weight to the matter. This week the DOJ asked the courts for permission to help settle disputes brought by state and local governments against opioid manufacturers and distributors.
-
Sorrento Therapeutics, Inc. nabbed regulatory approval for ZTlido, a non-opioid pain treatment in the form of a super-sticky patch.
-
Endo Announces Appointment of Dr. Sharad S. Mansukani to Board of Directors and Resignation of Mr. Douglas S. Ingram
11/8/2017
Ingram's decision to resign as a director from the Company's Board of Directors effective November 6, 2017 is due to his appointment as President and CEO of Sarepta Therapeutics earlier this year.
-
Endo Pharma Caves To The FDA, Agrees To Yank Opana ER From Market
7/7/2017